Sandoz Egypt launches drugs for organ transplant

The new medications can improve patient outcomes as well, the statement noted.

Country Head for Sandoz Egypt and Libya Sameh el Bagoury commented, “The area of transplantation is important for Sandoz and we are excited by the opportunity this launch offers in terms of wider patient access, greater government healthcare coverage, and Egyptian physicians education that can create a renewed sense of hope for patients.”

The immunosuppressant drugs are Tacrolimus 0.5 gram and 1 gm as well as Mycophenolate Mofetil 500 milligrams, the statement elaborated.

“The introduction of Tacrolimus is of particular importance due to its integral role in enhancing patient and graft survival amongst the immunosuppressant portfolios,” Sandoz highlighted.

The virtual launch of the drugs was held under the patronage of the Egyptian Society of Nephrology and Transplantation.